Loading...
XNAS
IRWD
Market cap770mUSD
Jul 10, Last price  
4.49USD
1D
-2.10%
1Q
28.65%
Jan 2017
-69.46%
IPO
-59.81%
Name

Ironwood Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:IRWD chart
P/E
30.77
P/S
2.50
EPS
0.15
Div Yield, %
—
Shrs. gr., 5y
2.04%
Rev. gr., 5y
-5.33%
Revenues
296m
-15.72%
3,140,00010,464,00022,216,00036,102,00043,857,00065,871,000150,245,00022,881,00076,436,000149,555,000273,957,000298,276,000346,639,000428,413,000389,523,000413,753,000410,596,000442,735,000351,410,000296,151,000
Net income
24m
+2,629.20%
-37,180,000-52,752,000-53,874,000-71,185,000-52,981,000-64,852,000-72,624,000-272,812,000-189,618,000-142,669,000-81,708,000-116,937,000-282,368,00021,505,000106,176,000528,448,000175,065,000-1,002,239,000880,00024,017,000
CFO
127m
+22.69%
-33,532,000-6,759,000-28,195,000-3,998,000-67,899,000-75,237,000-69,633,000-273,355,000-155,568,000-106,927,000-25,433,000-99,563,000-70,882,00010,725,000168,836,000261,895,000273,763,000183,427,000103,549,000127,044,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
URL
https://www.ironwoodpharma.com/
IPO date
Feb 03, 2010
Employees
219
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT